WO2010119455A3 - An injectable sustained release pharmaceutical composition - Google Patents
An injectable sustained release pharmaceutical composition Download PDFInfo
- Publication number
- WO2010119455A3 WO2010119455A3 PCT/IN2010/000243 IN2010000243W WO2010119455A3 WO 2010119455 A3 WO2010119455 A3 WO 2010119455A3 IN 2010000243 W IN2010000243 W IN 2010000243W WO 2010119455 A3 WO2010119455 A3 WO 2010119455A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- sustained release
- release pharmaceutical
- injectable sustained
- injectable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to an injectable pharmaceutical composition comprising antipsychotic agents having basic groups.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN978MU2009 | 2009-04-15 | ||
IN978/MUM/2009 | 2009-04-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010119455A2 WO2010119455A2 (en) | 2010-10-21 |
WO2010119455A3 true WO2010119455A3 (en) | 2011-01-27 |
Family
ID=42982942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2010/000243 WO2010119455A2 (en) | 2009-04-15 | 2010-04-15 | An injectable sustained release pharmaceutical composition |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010119455A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120121706A1 (en) * | 2009-04-10 | 2012-05-17 | Tufts Medical Center, Inc. | PAR-1 Activation by Metalloproteinase-1 (MMP-1) |
TWI592170B (en) * | 2012-07-26 | 2017-07-21 | Hisamitsu Pharmaceutical Co | Adhesive and its manufacturing method |
EP3193837A1 (en) * | 2014-08-14 | 2017-07-26 | Alrise Biosystems GmbH | Injectable formulations of asenapine |
US11154510B2 (en) | 2015-06-11 | 2021-10-26 | Alrise Biosystems Gmbh | Process for the preparation of drug loaded microparticles |
CN104940150B (en) * | 2015-06-16 | 2020-11-20 | 黑龙江大学 | Preparation method of paliperidone sustained-release microsphere injection |
JP7149287B2 (en) | 2016-12-20 | 2022-10-06 | エルテーエス ローマン テラピー-ジステーメ アーゲー | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
US20180193283A1 (en) | 2016-12-20 | 2018-07-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
EP3644973B1 (en) | 2017-06-26 | 2021-03-24 | LTS LOHMANN Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
BR112020026099A2 (en) | 2018-06-20 | 2021-03-23 | Lts Lohmann Therapie-Systeme Ag | transdermal therapeutic system containing asenapine |
WO2020091845A1 (en) * | 2018-10-29 | 2020-05-07 | University Of South Florida | Lithium cholesterol compositions and methods of treatment for alzheimer's disease and neurological disorders |
EP4319721A1 (en) * | 2021-04-07 | 2024-02-14 | Proneurogen, Inc. | Extended-release injectable gel formulations containing angiotensin-(1-7) oligopeptides or variants thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020132007A1 (en) * | 1998-03-18 | 2002-09-19 | University Technology Corporation | Sustainded-release composition including amorphous polymer |
WO2005032523A1 (en) * | 2003-09-30 | 2005-04-14 | Acusphere, Inc. | Injectable, oral, or topical sustained release pharmaceutical formulations |
-
2010
- 2010-04-15 WO PCT/IN2010/000243 patent/WO2010119455A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020132007A1 (en) * | 1998-03-18 | 2002-09-19 | University Technology Corporation | Sustainded-release composition including amorphous polymer |
WO2005032523A1 (en) * | 2003-09-30 | 2005-04-14 | Acusphere, Inc. | Injectable, oral, or topical sustained release pharmaceutical formulations |
Also Published As
Publication number | Publication date |
---|---|
WO2010119455A2 (en) | 2010-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010119455A3 (en) | An injectable sustained release pharmaceutical composition | |
EP2240022A4 (en) | Pharmaceutical compositions | |
GB0814695D0 (en) | Pharmaceutical compositions | |
IL228817A0 (en) | Pharmaceutical composition | |
EP2373681A4 (en) | Pharmaceutical compositions | |
WO2012042371A3 (en) | Pharmaceutical composition | |
AP2010005380A0 (en) | Extracellular matrix compositions. | |
PT2323623T (en) | Pharmaceutical compositions | |
EP2444087A4 (en) | Pharmaceutical composition having improved solubility | |
ZA201102715B (en) | Solid pharmaceutical composition | |
IL208387A0 (en) | Pharmaceutical composition | |
ZA201100871B (en) | Solid pharmaceutical composition | |
ZA201006224B (en) | Pharmaceutical composition | |
UA96476C2 (en) | Pharmaceutical composition comprising irbesartan | |
ZA201100529B (en) | Solid pharmaceutical composition comprising exemestane | |
GB2464200B (en) | Pharmaceutical composition | |
IL206487A0 (en) | Pharmaceutical compositions | |
EP2311493A4 (en) | Cytotoxic composition | |
GB0817969D0 (en) | Pharmaceutical composition | |
HK1182939A1 (en) | Stable pharmaceutical composition | |
GB0800659D0 (en) | Pharmaceutical Compositions | |
EP2327671A4 (en) | Cement-setting-time accelerator compositions | |
AU2008902603A0 (en) | Injectable Formulations | |
IL199679A0 (en) | Injectable pharmaceutical composition | |
GB0804485D0 (en) | Novel pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10764178 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10764178 Country of ref document: EP Kind code of ref document: A2 |